Blood/Marrow Transplantation for Treatment of Chronic Myeloid Leukemia

While treatment is believed to influence disease§outcome, the wide variation in published survival and§remission rates among chronic myeloid leukemia (CML)§patients demonstrates that the effectiveness of§treatment appears to be modified by patient§characteristics, disease features, and disease§management approaches. Future improvements in the§treatment of CML are dependent on our ability to§distinguish between patients who are likely to have§long-term disease free survival and those who are §not.§Between June 1982 and December 2002, 234 patients§with CML in first chronic phase (CP) were treated at§the City of Hope National Medical Center with an§allogeneic blood or marrow transplant (Allo-BMT)§using histocompatible sibling donors. This§retrospective case-series study examined the role of§patient, disease, and treatment factors collected§both at the time of diagnosis and Allo-BMT to assess§the predictive value of these factors on a patient?s§risk for cytogenetic relapse (CR) and/or death§following Allo-BMT. This study also explored the§predictive value of three generally accepted§prognostic scoring systems (Sokal, Hasford, Gratwohl)§in this large single center Allo-BMT population.